PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1739157
PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1739157
Global HIV Injections Market to Reach US$3.0 Billion by 2030
The global market for HIV Injections estimated at US$1.1 Billion in the year 2024, is expected to reach US$3.0 Billion by 2030, growing at a CAGR of 17.6% over the analysis period 2024-2030. Hospital Pharmacy Distribution Channel, one of the segments analyzed in the report, is expected to record a 19.2% CAGR and reach US$1.8 Billion by the end of the analysis period. Growth in the Drugs Stores & Retail Pharmacies Distribution Channel segment is estimated at 15.1% CAGR over the analysis period.
The U.S. Market is Estimated at US$311.6 Million While China is Forecast to Grow at 23.4% CAGR
The HIV Injections market in the U.S. is estimated at US$311.6 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$679.1 Million by the year 2030 trailing a CAGR of 23.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 12.9% and 15.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 14.1% CAGR.
Why Are Long-Acting HIV Injections Reshaping Treatment Adherence and Outcomes?
HIV injections, particularly long-acting injectable antiretroviral therapies (ART), are transforming HIV treatment paradigms by improving adherence, reducing pill burden, and mitigating stigma associated with daily oral medication. These injectable formulations-administered bi-monthly or monthly-have emerged as a clinically proven alternative to oral ART regimens for individuals with stable viral suppression. The convenience and discretion associated with injectable ART have the potential to improve treatment retention and overall quality of life for people living with HIV.
Currently, the most prominent options include long-acting injectable cabotegravir and rilpivirine combinations, with more candidates in late-stage development. These regimens are especially impactful in underserved populations, individuals with adherence challenges, and settings where healthcare access is irregular. Beyond treatment, long-acting injectable pre-exposure prophylaxis (PrEP) options are also showing strong promise for at-risk populations, offering longer protection intervals and reducing the daily adherence requirement compared to oral PrEP.
How Is Innovation in Formulation and Delivery Enhancing the Impact of HIV Injections?
Advances in drug formulation, depot technologies, and intramuscular delivery mechanisms are making HIV injections safer, more effective, and easier to administer. Long-acting nanosuspensions and extended-release microsphere technologies allow for sustained drug release with minimal systemic fluctuation. These formulations maintain therapeutic plasma concentrations for extended periods, which not only improves efficacy but also reduces the risk of resistance development due to missed doses.
Clinical trials and real-world studies continue to evaluate alternate dosing frequencies, injection site tolerability, and self-administration feasibility. Auto-injector technologies, needleless delivery, and combination injections with multi-mechanism ART compounds are being explored to further enhance convenience. Meanwhile, pharmacovigilance and global access initiatives are working to ensure equitable distribution, especially in high-burden regions like sub-Saharan Africa where logistical and cost barriers remain significant.
Which Markets and Populations Are Driving Demand for Injectable HIV Treatments?
North America and Western Europe are currently leading the adoption of injectable HIV therapies due to strong healthcare infrastructure, regulatory approvals, and favorable reimbursement models. In the U.S., long-acting injectable ART is already being integrated into clinical HIV care, while the EU is rapidly following suit. The global South, including Africa and Southeast Asia, represents the most significant long-term opportunity, given the high HIV prevalence and the potential public health impact of simplified dosing regimens.
High-risk populations such as MSM (men who have sex with men), sex workers, and transgender individuals are primary targets for injectable PrEP programs. For treatment, patients with adherence difficulties, mental health challenges, or unstable living conditions are key beneficiaries of long-acting options. NGOs, public health agencies, and international donor programs are increasingly including injectable therapies in HIV prevention and treatment protocols as part of global UNAIDS goals for ending the HIV epidemic.
The Growth in the HIV Injections Market Is Driven by Several Factors…
The growth in the HIV injections market is driven by several factors including pharmaceutical innovation in long-acting formulations, increased demand for adherence-friendly therapies, and global initiatives to improve ART access. Technologically, sustained-release injectable platforms and nanoparticle delivery systems are enabling extended therapeutic coverage and reducing dosing frequency. Regulatory approvals and clinical guideline updates are supporting market entry in high-income countries, while donor-led programs are accelerating pilot deployments in low-income regions.
From an end-use perspective, growing demand for PrEP among high-risk populations, improved treatment outcomes among non-adherent patients, and healthcare provider preference for simplified monitoring are propelling injectable adoption. As stigma, adherence fatigue, and global access challenges persist, HIV injections offer a compelling alternative to traditional oral regimens-one that aligns with the global effort to improve quality of life and viral suppression outcomes for all individuals living with or vulnerable to HIV.
SCOPE OF STUDY:
The report analyzes the HIV Injections market in terms of units by the following Segments, and Geographic Regions/Countries:
Segments:
Distribution Channel (Hospital Pharmacy, Drugs Stores & Retail Pharmacies, Other Distribution Channels)
Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Select Competitors (Total 41 Featured) -
TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.
We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.
We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.
As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.
To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!
APRIL 2025: NEGOTIATION PHASE
Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.
JULY 2025 FINAL TARIFF RESET
Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.
Reciprocal and Bilateral Trade & Tariff Impact Analyses:
USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.
Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.
COMPLIMENTARY PREVIEW
Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.